Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DB-1419 |
| Synonyms | |
| Therapy Description |
DB-1419 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting CD274 (PD-L1) and CD276 (B7-H3) linked to a DNA topoisomerase I inhibitor, which potentially induces cytotoxicity in CD276 (B7-H3)-expressing tumor cells and inhibits tumor growth (Eur J Cancer 211 (2024): 114702; Cancer Res (2025) 85 (8_Supplement_2): CT121). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DB-1419 | DB 1419|DB1419 | CD276 Antibody 21 PD-L1/PD-1 antibody 133 | DB-1419 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting CD274 (PD-L1) and CD276 (B7-H3) linked to a DNA topoisomerase I inhibitor, which potentially induces cytotoxicity in CD276 (B7-H3)-expressing tumor cells and inhibits tumor growth (Eur J Cancer 211 (2024): 114702; Cancer Res (2025) 85 (8_Supplement_2): CT121). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06554795 | Phase Ib/II | DB-1419 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |